Prevail Therapeutics   Report issue

For profit Phase 2
Founded: New York NY United States (2017)
Status: Acquired by Eli Lilly (2020)

Organization Overview

First Clinical Trial
2019
NCT04127578
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Prevail Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aphasia, Primary Progressive (Phase 2)

Dementia (Phase 2)

Frontotemporal Dementia (Phase 2)

Gaucher Disease (Phase 2)

Parkinson Disease (Phase 2)

Pick Disease of the Brain (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 7